Tango Therapeutics, Inc.
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G for Tango Therapeutics Inc. reporting a 6.0% beneficial stake in Tango common stock. The filing cites aggregate beneficial ownership of 9,742,402.80 shares, with shared voting power over 9,740,098.80 shares and shared dispositive power over 9,740,206.80 shares.
Tango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.
Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tngx-ex99_1.htm EX-99.1 EX-99.1 Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer foll
Over the past 7 days, alphai's AI scored 1 news story mentioning TNGX (Tango Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TNGX coverage spans corporate actions, earnings and insider activity.
In the last 30 days, TNGX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($736K). The most active reporter was Crystal Adam, President, R&D, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
This is a new beneficial-ownership disclosure that can affect perceived shareholder base and potential governance influence, but it is not an operational catalyst.
The earnings miss and cost spike (G&A nearly doubled) are the immediate drivers of downside risk for TNGX, despite ongoing late-stage clinical progress.
The filing adds fresh clinical efficacy detail and a stated intent to pursue a registrational Phase 3 path, which can re-rate risk for TNGX.
Board/officer change plus defined separation economics can shift near-term sentiment and governance expectations, but it is not tied to operating or clinical milestones in the filing.
Routine 10b5-1 insider selling by the President of R&D, likely more informational than fundamental, with limited near-term trading signal.
alphai scores every news story that mentions TNGX with an AI model for sentiment and relevance, and aggregates insider trades from Tango Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G for Tango Therapeutics Inc. reporting a 6.0% beneficial stake in Tango common stock. The filing cites aggregate beneficial ownership of 9,742,402.80 shares, with shared voting power over 9,740,098.80 shares and shared dispositive power over 9,740,206.80 shares.
2 min readTango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.
4 min readTango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tngx-ex99_1.htm EX-99.1 EX-99.1 Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer foll
4 min readTango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001819133 0001819133 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31,
2 min readCrystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $27.24 ($26.79–$27.35, $0.74M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readCanaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.
5 min readCrystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $29.59 ($29.34–$30.25, $0.80M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readStock index futures pointed to a lower open as tech and chip stocks slid after renewed selling in semiconductors and a New York Times report said OpenAI may delay its IPO until 2027. Nasdaq 100 futures were down 1.1% at 8:00am ET; S&P 500 futures down 0.4%. Analysts cited valuation/positioning shifts. Oil fell to $69.18; 2-year yields declined.
7 min readTango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001819133 0001819133 2026-06-19 2026-06-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 19,
2 min readTango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d81492dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version TANGO THERAPEUTICS, INC. (a Delaware corporation) 18,166,667 Shares of Common Stock And Pre-Funded Warrants to Purchase 1,833,395 of Common Stock UNDERWRITING AGREEMENT June 9, 2026 J.P. Morgan Securities LLC Le
2 min read
